
John McGahon unlikely to be elected and could be outpolled by Fine Gael running mate Paul Butterly
ONEOK Inc. stock outperforms competitors on strong trading dayCanadian Prime Minister Trudeau flies to Florida to meet with Trump after tariffs threat WEST PALM BEACH, Fla. (AP) — Canadian Prime Minister Justin Trudeau has flown to Florida to have dinner with President-elect Donald Trump at his Mar-a-Lago club after Trump threatened to impose sweeping tariffs on Canadian products. Joining Trump and Trudeau at dinner were Trump's picks for commerce secretary, interior secretary and national security adviser, and the three men's wives. From the Canadian side, the dinner guests included Public Safety Minister Dominic LeBlanc, whose responsibilities include border security. Trump’s transition did not respond to questions about what they had discussed or whether the conversation alleviated Trump’s concerns about the border. A smiling Trudeau declined comment upon returning to his West Palm Beach hotel late Friday. Emboldened 'manosphere' accelerates threats and demeaning language toward women after US election CHICAGO (AP) — An emboldened fringe of right-wing “manosphere” influencers has seized on Donald Trump’s presidential win to justify and amplify misogynistic derision and threats online. Many have appropriated a 1960s abortion rights rallying cry, declaring “Your body, my choice,” and have been using it publicly on college campuses and even in public schools. While none of the current online rhetoric is being amplified by Trump, experts say many young men see the former president’s return to the White House as vindication of their views on women. For many women, the words represent a worrying harbinger of what might lie ahead as some men perceive the election results as a rebuke of reproductive rights and women’s rights. Syrian insurgents are inside Aleppo in a major setback for Assad as government forces regroup BEIRUT (AP) — Thousands of Syrian insurgents have fanned out inside Syria's largest city Aleppo a day after storming it with little resistance from government troops. Syria's army said troops have redeployed to prepare for a counteroffensive. Witnesses said insurgents were seen Saturday at landmarks in Aleppo for the first time since 2016, when they were expelled by government forces backed by Russia and Iran. The surprise offensive is a major embarrassment for Syrian President Bashar Assad, who has regained total control of the city eight years ago. Israeli strike in Gaza allegedly kills workers with World Central Kitchen charity DEIR AL-BALAH, Gaza Strip (AP) — An Israeli airstrike on a car in Gaza has killed five people, according to a senior Palestinian health official. An aid worker says three of the people killed were employees of the charity World Central Kitchen. The charity's aid delivery efforts in Gaza were temporarily suspended earlier this year after an Israeli strike killed seven of its workers. Israel's military says it struck a wanted militant who had been involved in the Hamas attack that sparked the war. In a later statement, it said that the alleged attacker had worked with WCK and it asked “senior officials from the international community and the WCK administration to clarify” how that had come about. Fishers at a Lebanese port hope ceasefire with Israel means normal life is returning TYRE, Lebanon (AP) — The ceasefire between Israel and Hezbollah brought hope for normality back to many in southern Lebanon on Friday. That includes fishers who’ve long launched their single-engine wooden boats into the Mediterranean at dawn. During the last two months, Israel imposed a siege that kept hundreds of fishers at this ancient Phoenician port on shore. That upended their lives in a major hit for the industry. The port siege also cut people off from the key ingredients for traditional Lebanese dishes. As war devastated their country, the loss of fish damaged a deep association with home. The possibility of renewed fishing is helping fuel hope. How Brazilian police say Bolsonaro plotted a coup to stay in office SAO PAULO (AP) — Brazil’s Federal Police have formally accused former far-right President Jair Bolsonaro and 36 others of plotting a coup to keep him in office. The plot was allegedly comprised of several components and substantiated by evidence and testimony in the agency's 884-page report. The pieces of the puzzle include laying the groundwork by systematically sowing distrust of the electoral system among the populace. It also includes drafting a decree to give the plot a veneer of legal basis and pressuring top military brass to go along with the plan. Bolsonaro and his main allies have denied any wrongdoing or involvement and accuse authorities of political persecution. More than 100 arrested as Georgian police clash with protesters over suspension of EU talks TBILISI, Georgia (AP) — More than 100 demonstrators were arrested overnight in Georgia as protesters clashed with police following the government’s decision to suspend negotiations to join the European Union, the country’s Interior Ministry said. Friday marked the second straight night of protests after Prime Minister Irakli Kobakhidze of the country’s ruling Georgian Dream party announced the suspension the previous day. The Associated Press saw protesters in Tbilisi being chased and beaten by police as demonstrators rallied in front of the country's parliament building. The violence follows Georgian Dream’s disputed victory in the Oct. 26 election, which was widely seen as a referendum on the country’s aspirations to join the European Union. Romania's parliamentary vote risks being overshadowed by presidential race chaos BUCHAREST, Romania (AP) — Romanians are preparing to go to the polls in a parliamentary vote that will determine a new government and prime minister to lead the European Union and NATO member country. However, Sunday's vote is sandwiched between a two-round presidential race and is overshadowed by controversies and chaos following the outcome of the first vote. While the president has significant decision-making powers in areas such as national security and foreign policy, the prime minister is the head of the nation’s government. Sunday’s vote will determine the formation of the country’s 466-seat legislature. North Korea's Kim vows steadfast support for Russia’s war in Ukraine SEOUL, South Korea (AP) — North Korean leader Kim Jong Un said his country will “invariably support” Russia’s war in Ukraine as he met Russia's visiting defense chief. A Russia military delegation led by Defense Minister Andrei Belousov arrived in North Korea on Friday as international concerns about the two countries’ expanding cooperation deepened after North Korea sent thousands of troops to Russia. During a Friday meeting, Kim and Belousov reached “a satisfactory consensus” on issues on how to further boost strategic partnership and defend each country’s sovereignty and security interests, state media said. Great Lakes, Plains and Midwest forecast to be hit with snow and dangerous cold into next week BUFFALO, N.Y. (AP) — The first big snow of the season has the potential to bury towns in New York along lakes Erie and Ontario during a hectic holiday travel and shopping weekend. Forecasters says winter storm conditions could persist into next week and cause hazards in the Great Lakes, Plains and Midwest regions. Forecasters predict 4 to 6 feet of blowing and drifting snow could fall in Watertown and other areas east of Lake Ontario through Monday. New York Gov. Kathy Hochul has declared a disaster emergency in affected areas.
OpenAI releases Sora, its buzzy AI video-generation tool
Wallaroos end 17-year wait in Canberra against one of rugby's biggest names
Williams Cos. stock rises Tuesday, outperforms marketHow To Watch Borussia Dortmund vs Bayern Munich, Bundesliga 2024–25 Free Live Streaming Online & Match Time in India? Get Der Klassiker Live Telecast on TV & Football Score Updates in IST?
Mike Thompson Slammin' Sports [email protected] Visit us on social media: Facebook X LinkedIn Instagram Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.In 2020, Borderland Pride asked the township of Emo, Ont. (pop. 1,300) to proclaim Pride Month and fly the Pride flag. In a 3-2 vote, the council declined. It was a petty decision; Pride proclamations are generally considered pro forma, and Emo’s refusal was a bad look for a township seeking to attract business and newcomers. In fairness, Emo only had four such requests that year, two of them from Borderland Pride. This was a far cry from the 1990s, when Hamilton and London discriminated against Pride by excluding it from similar resolutions passed for everyone else. If Borderlands Pride had been smart, it would simply have gone ahead with its celebration, demonstrated support within the community, shamed the council and worked to turf the mayor and unsympathetic councillors at the next municipal election. Instead, it took Emo to the Ontario Human Rights Commission. As Borderlands Pride underlined in an open letter sent to the council in April, this action cost Emo’s taxpayers “tens of thousands of dollars” in legal fees at a time when Emo was “soliciting public donations to keep the lights on at its public library, (and) accepting handouts from the local food bank.” It told Emo that it would agree to a settlement if the township published an apology; gave Borderlands compensation (a lesser amount than what was asked at the tribunal); ordered diversity and inclusion training for its members and agreed to “adopt Pride proclamations in the future without stripping out their 2SLGBTQIA+-affirming language.” Emo declined and went through the full tribunal process instead. I am a gay man who has fought for LGB and T civil rights since the 1970s; Borderland Pride’s action angers and appalls me. Is there a better way to destroy the public goodwill we worked so long to achieve and feed the populist backlash building from a decade of activist overreach? Apparently, yes. The tribunal’s adjudicator, Karen Dawson, ruled on Nov. 20 that by voting not to proclaim Pride Month, the township of Emo and its mayor, Harold McQuaker, discriminated against Borderland Pride. She ordered the township to pay the organization $10,000. Further, the mayor was ordered to pay Borderland Pride $5,000 and, along with the township’s chief administrative officer, to take the Ontario Human Rights Commission’s “ Human Rights 101 ” course. The tribunal’s reasoning for its decision was just as confounding. Back when the township was voting on whether to make a Pride proclamation, the mayor told council, “There’s no flag being flown for the other side of the coin ... there’s no flags being flown for the straight people.” The tribunal found that this factually accurate statement was discriminatory because it “demonstrated a lack of understanding” of the Pride flag’s importance and was “demeaning and disparaging of the LGBTQ2 community of which Borderland Pride is a member....” The mayor’s argument that heterosexuals don’t have special recognition is common. In the 70s, our response was, “That’s because it’s Straight Pride Day 365 days a year.” But today, we’re regularly celebrated in every field from politics to finance and the arts, and the Alphabet calendar has more niche days than anyone can remember. Our inclusion under human rights legislation was especially important in the 20th century. We were fired, denied housing and purged from the civil service and military. We were beaten without impunity, unable to seek protection from police, who mocked and outed us — and even beat us themselves. Those were the kinds of important discrimination cases we brought to newly created federal and provincial human rights commissions. Similarly, that’s why Toronto’s first proclamation of Pride Day in 1991, and the other civic proclamations that followed, was so important. Conservative politicians and religious leaders of the day fanned hatred against us. They accused us of pedophilia, scapegoated us for the AIDS pandemic and mocked our deaths. Pride proclamations signalled that we were considered valuable community members worthy of equal treatment and respect. But today, such symbolic support has metastasized into absurdity. Pride has morphed from a day to a season and our claims before human rights commissions are often jawdropping and vexatious . Worse, even in the most outlandish cases, the process is the punishment: Complainants’ costs are paid for regardless of the merit of their case, whereas the accused must foot their own legal bills. The message is clear: Even if innocent, capitulate on accusation or suffer financial pain. More troubling, tribunals now often use their unelected, unaccountable and quasi-judicial power to impose Orwellian judgements. In this case, a factually accurate comment questioning special treatment for a specific group has resulted in severe financial penalties against a struggling, rural township, and a fine and forced re-education for its mayor and chief administrative officer. Ultimately, this is about the unilateral power of an unelected, unaccountable government agency to compel speech. Public officials must not be allowed to discriminate against us, but neither should they be forced to proactively support us. In the 21st century, we have full civil rights, including equal marriage and the ability to adopt. It is demeaning to our pride to run to the state when an idiot chooses to be an ass. In my view, Borderland Pride shamed LGB and T communities by trivializing our historic struggles for equality. It also fed the growing, and understandable, backlash against us. By finding in its favour, the Ontario Human Rights Commission lost sight of its mission, broke public confidence in its legitimacy and provided a counter-productive example of left-wing authoritarianism. National Post
MASSIVE SCAM: Thread on European Healthcare Serves As Warning for Americans Demanding Socialized MedicineWAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the "Company” or "Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of Aclaris' Board of Directors (the "Committee”) granted nonstatutory stock options to purchase an aggregate of 251,000 shares of its common stock and 73,000 restricted stock units to 4 new employees under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the "2024 Inducement Plan”). In addition, also effective December 2, 2024, the Committee granted Hugh Davis, Ph.D, Aclaris' new President and Chief Operating Officer, nonstatutory stock options to purchase 375,000 shares of its common stock and 107,000 restricted stock units under the 2024 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individuals' entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $3.96 per share, which is equal to the closing price of Aclaris' common stock on December 2, 2024. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third, and fourth anniversaries of the recipient's start date, subject to each such employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2024 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock unit award agreement, as applicable, covering the grant. Aclaris Therapeutics Contact: [email protected]WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs”), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here . Key opinion leaders will include John R. Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss the unmet medical need and current treatment landscape for patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF). The event will focus on Tectonic's lead program, TX45, an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in patients with Group 2 PH-HFpEF in an ongoing Phase 1b hemodynamic proof-of-concept study and a Phase 2 clinical proof-of-concept study. A live question and answer session will follow the formal presentations. About the Key Opinion Leaders: Professor John R. Teerlink, MD, FACC, FAHA, FESC, FHFA, FHFSA, FRCP (London) Professor Teerlink is Professor of Medicine at the University of California San Francisco (UCSF). After graduating from Swarthmore College with a Religion major, he received an MD from Harvard Medical School and completed his Internal Medicine residency and Cardiovascular Medicine fellowship at UCSF, as well as post-doctoral fellowships in Cardiovascular pharmacology (Hoffman-LaRoche; Basel, Switzerland), echocardiography (UCSF) and heart failure (UCSF-affiliated hospital). He is actively involved in the design and execution of many heart failure clinical trials, serving on endpoint, data monitoring, steering and executive committees for numerous international studies investigating a variety of new pharmacologic therapies, as well as stem cell and gene therapies, diagnostic modalities and other devices. He was the lead clinical investigator for the serelaxin development program, serving as Principal Investigator for Pre-RELAX-AHF, RELAX-AHF, RELAX-AHF-2 and RELAX-Repeat, and as a steering committee member for RELAX-AHF-Asia. Dr. Teerlink has served on the US FDA Cardiovascular and Renal Drug Advisory Committee, as well as on other FDA drug, device, diagnostics, and vaccine panels and serves as a consultant on pre-clinical and clinical development programs in multiple areas of cardiology, as well as in non-cardiovascular indications. Dr. Teerlink was a founding physician member of the American Association of Heart Failure Nurses and is a Past President of the Heart Failure Society of America. He was an Associate Editor for the Journal of Cardiac Failure, Guest Editor-in-Chief and Associate Editor for JACC: Heart Failure, and is a clinical scholar presenting many lectures and over 300 publications, including a chapter on Acute Heart Failure in Braunwald's Heart Disease textbook. He was profiled in The Lancet as an internationally recognized leader in heart failure. Raymond L. Benza, MD, FACC, FAHA, FACP Dr. Benza is a Professor and System Director of Pulmonary Hypertension at the Icahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital. He is a fellow of the American College of Physicians, the American Heart Association Council on Clinical Cardiology, the American College of Chest Physicians and the American College of Cardiology. He is a diplomat of the American Board of Internal Medicine with certification in the subspecialties of cardiovascular diseases and advanced heart failure and transplantation. Dr. Benza currently holds administrative positions in the Pulmonary Vascular Research Institute and the International Society of Heart and Lung Transplantation and is the former treasurer of that society. He served on President Barak Obama's Advisory Committee on Organ Transplantation (ACOT) in the Health Resources and Services Administration for 4 years and was knighted in 2015 by his Royal Highness Vittorio Emanuele of Italy for his philanthropic work in patients with pulmonary arterial hypertension and was admitted to the Association of University Cardiologists. He sits on multiple journal editorial committees and is the Steering Committee Chair for several industry trials in PAH. His primary clinical interests are the evaluation and treatment of advanced congestive heart failure, cardiac transplantation, and pulmonary arterial hypertension (PAH). He participates in major clinical studies of new therapies for the treatment of heart failure, mechanical support, and pulmonary hypertension. Dr. Benza is a funded investigator for the National Institutes of Health and the American Heart Association for his work in pulmonary arterial hypertension focusing on risk stratification, pharmacogenomics and new device therapies for this disease state. About TX45, a long-acting Fc-relaxin fusion protein TX45 is an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary and systemic vasodilator with lusitropic, anti-fibrotic and anti-inflammatory activity. In normal human physiology, relaxin is upregulated during pregnancy where it exerts vasodilative effects, reduces systemic and pulmonary vascular resistance and increases cardiac output to accommodate the increased demand for oxygen and nutrients from the developing fetus. Relaxin also exerts anti-fibrotic effects on pelvic ligaments to facilitate delivery of the baby. About Group 2 Pulmonary Hypertension in HFpEF The World Health Organization has defined five groups of pulmonary hypertension ("PH”). Tectonic is focused on the Group 2 subtype, a condition that develops due to left-sided heart disease, specifically pulmonary hypertension secondary to left heart failure with preserved ejection fraction ("PH-HFpEF”). In patients with PH-HFpEF, chronic heart failure leads to increased blood pressure in the pulmonary arteries, exerting severe strain on the right side of the heart, which adapts poorly to the increased pressure. This increased pulmonary pressure gradually causes worsening exercise capacity, shortness of breath and right-sided heart failure which can lead to death. Although several Group 1 PH (Pulmonary Arterial Hypertension, PAH) medications have been explored in Group 2 PH, to date, no medications have been approved for its treatment. About Tectonic Tectonic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs”). Leveraging its proprietary technology platform called GEODeTM (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow on LinkedIn . Forward-Looking Statements This press release contains "forward-looking statements” within the meaning of the "safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements. These statements may be identified by words such as "aims,” "anticipates,” "believes,” "could,” "estimates,” "expects,” "forecasts,” "goal,” "intends,” "may,” "plans,” "possible,” "potential,” "seeks,” "will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include statements regarding: the design, objectives, initiation, timing, progress and results of clinical trials of Tectonic's product candidates, including the ongoing Phase 1b and Phase 2 clinical trials for TX45 in Group 2 PH-HFpEF; and the potential properties and benefits of TX45. These forward-looking statements are based on Tectonic's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Tectonic's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, heightened inflation and uncertain credit and financial markets, on Tectonic's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Tectonic's ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Tectonic's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors” in Tectonic's quarterly report on Form 10-Q filed with the SEC on November 12, 2024, and in other filings that Tectonic makes and will make with the SEC in the future. Tectonic expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit www.tectonictx.com and follow on LinkedIn . Source: Tectonic Therapeutic CONTACT: Contacts: Investors: Dan Ferry LifeSci Advisors (617) 430-7576 [email protected] Media: Kathryn Morris The Yates Network (914) 204-6412 [email protected]
Acting Maharashtra Chief Minister Eknath Shinde's health took a sudden turn on Saturday, as he experienced a fever shortly after arriving in his native village in Satara, a report said. According to Dr Parte, the family physician, Shinde had a mild fever of 99 degrees Celsius and was administered saline. The doctor confirmed that Shinde's condition is improving and attributed the symptoms to a viral infection, noting that he is also experiencing mild cough and cold. In light of his illness, the acting CM cancelled all his scheduled meetings in Mumbai and chose to return to his village to rest, sparking speculation about his future role in the Mahayuti government. Maharashtra Chief Minister Swearing-In Ceremony To Be Held on December 5 at Mumbai's Azad Maidan . Maharashtra News : Eknath Shinde की तबियत खराब हुई #maharashtra #eknathshinde pic.twitter.com/1GLxM3BtJJ — News18 India (@News18India) November 30, 2024 (SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter, Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)Qatar tribune DPA Seoul South Korea’s Ministry of Justice has banned President Yoon Suk Yeol from leaving the country, as the country’s political crisis deepens. The South Korean news agency Yonhap reported on Monday that the reason for the travel ban is the ongoing investigation against Yoon on suspicion of high treason. Yoon unexpectedly imposed martial law on his country last Tuesday night and hours later, after massive political resistance, repealed the order. On Saturday evening, a motion by the opposition to impeach the president in parliament failed. However, public pressure against the 63-year-old continues. Copy 10/12/2024 10